广泛期177Lu-PSMA抑制剂治疗转移性去势抵抗性前列腺癌的治疗后关键器官剂量测定:单中心结果
该单中心回顾性研究分析了10例转移性去势抵抗性前列腺癌患者共51个周期的177Lu-PSMA抑制剂肽受体放射性配体治疗(4至6周期,间隔8至10周),基于MIRD第16号方案估算肾脏、腮腺、下颌下腺和泪腺的辐射吸收剂量。肾脏平均吸收剂量为0.70 ± 0.24 Gy/GBq,腮腺为1.34 ± 0.78 Gy/GBq,下颌下腺为0.94 ± 0.45 Gy/GBq,泪腺为2.28 ± 1.29 Gy/GBq。作者认为,尽管部分患者肾脏吸收剂量超过ICRP关键剂量限值,但未观察到肾毒性所致死亡。
要点
- 10例患者共51个周期177Lu-PSMA抑制剂治疗,4至6周期,间隔8至10周。
- 肾脏平均吸收剂量0.70 ± 0.24 Gy/GBq,腮腺1.34 ± 0.78 Gy/GBq。
- 下颌下腺平均吸收剂量0.94 ± 0.45 Gy/GBq,泪腺2.28 ± 1.29 Gy/GBq。
核心结论
- 由于关键靶器官风险和最佳治疗剂量,患者特异性剂量测定是核素治疗的确定性因素。
- 即使4至6周期治疗患者的肾脏吸收剂量超过ICRP关键剂量限值,也未观察到肾毒性所致死亡。
- 对于生存率极低的患者群体,轻度增加的耐受辐射剂量是可接受的。
研究设计与样本
- 单中心回顾性分析,共纳入10例转移性去势抵抗性前列腺癌患者,分析51个周期的177Lu-PSMA抑制剂肽受体放射性配体治疗。
- 治疗为4至6周期,间隔8至10周。
- 基于MIRD第16号方案,在GE Xeleris功能成像工作站勾画感兴趣区,使用OLINDA/EXM 1.1模拟软件计算肾脏、腮腺、下颌下腺和泪腺的辐射吸收剂量。
主要发现
- 肾脏平均辐射吸收剂量为0.70 ± 0.24 Gy/GBq。
- 腮腺平均辐射吸收剂量为1.34 ± 0.78 Gy/GBq。
- 下颌下腺平均辐射吸收剂量为0.94 ± 0.45 Gy/GBq。
- 泪腺平均辐射吸收剂量为2.28 ± 1.29 Gy/GBq。
- 在4至6周期治疗且肾脏吸收剂量超过ICRP关键剂量限值的患者中,未观察到肾毒性所致死亡。
关键数值与推荐
- 关键器官包括肾脏、腮腺、下颌下腺和泪腺。
- 剂量估算依据MIRD第16号方案。
- 肾脏吸收剂量超过ICRP关键剂量限值的情况出现在接受4至6周期治疗的患者中。
临床怎么用
- 作者认为,患者特异性剂量测定是核素治疗的确定性因素。
- 作者认为,对于生存率极低的患者群体,轻度增加的耐受辐射剂量是可接受的。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Lu-PSMA inhibitor peptide receptor radioligand therapy (RLT) is playing an increasing role in metastatic castration-resistant prostate cancer. We aimed to estimate the absorbed radiation doses for critical organs (eg, kidneys, parotid glands, submandibular glands, and lacrimal glands) of patients treated with 4 to 6 cycles by Lu-PSMA inhibitor RLT, retrospectively, and to evaluate the findings extensively in order to determine the critical organ radiation-absorbed limitations and the number of prospective RLT. MATERIALS AND METHODS: A total of 51 cycles Lu-PSMA inhibitor RLT in 10 patients was analyzed. Therapies have been applied in 4 to 6 cycles with 8 to 10 weeks' intervals. Dosimetric estimates of kidneys, parotid glands, submandibular glands, and lacrimal glands have been calculated based on MIRD scheme pamphlet no. 16. Regions of interest were drawn with GE Xeleris Functional Imaging Workstation. OLINDA/EXM 1.1 simulation software was used to calculate radiation-absorbed doses. RESULTS: Mean radiation-absorbed doses were 0.70 ± 0.24 Gy/GBq for kidneys, 1.34 ± 0.78 Gy/GBq for parotid glands, 0.94 ± 0.45 Gy/GBq for submandibular glands, and 2.28 ± 1.29 Gy/GBq for lacrimal glands. CONCLUSIONS: Due to the critical target organ risks and the optimal therapy doses, patient-specific dosimetry is a deterministic factor in radionuclide therapy. Even when the absorbed kidney doses were above the ICRP critical dose limits in patients who had 4 to 6 cycles of therapy, mortality due to nephrotoxicity has not been observed. Mild increased tolerated radiation dose is acceptable for the patient groups with very low survival rate.
引用
- Özkan A, Uçar B, Seymen H, et al. Posttherapeutic Critical Organ Dosimetry of Extensive 177Lu-PSMA Inhibitor Therapy With Metastatic Castration-Resistant Prostate Cancer: One Center Results. Clin Nucl Med. 2020. PMID: 32049721. doi:10.1097/RLU.0000000000002942
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。